Bone changes and fracture related to menstrual cycles and ovulation

Critical Reviews in Eukaryotic Gene Expression

Volumn 20, Issue 3, 2010, Pages 213-233

  Kalyan, Shirin ^a   Prior, Jerilynn C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Activins; Bone density; Bone fractures; Bone turnover; Estrogen; FSH; Inhibins; Menstrual cycle; Osteoporosis; Ovulation; Progesterone

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CYTOCHROME P450; DEOXYPYRIDINOLINE; ESTROGEN; FOLLITROPIN; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBIN A; INHIBIN B; LUTEINIZING HORMONE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN; PROGESTERONE; PYRIDINOLINE; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

AGING; AMENORRHEA; ARTICLE; BONE LESION; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CLIMACTERIUM; FEMALE; FRACTURE; HUMAN; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENTAL STRESS; MORBIDITY; OLIGOMENORRHEA; OSTEOLYSIS; OSTEOPOROSIS; OVULATION; PHYSICAL STRESS; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; WOMEN'S HEALTH; BONE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BONE AND BONES; FEMALE; FRACTURES, BONE; HUMANS; MENSTRUAL CYCLE; OSTEOPOROSIS; OVULATION;

EID: 79952277980     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v20.i3.30     Document Type: Article

References (131)

1. Albright F, Bloomberg F, Smith PH. Postmenopausal osteoporosis. Trans Assoc Am Phys. 1940;55:298-305.
2. Reifenstein EC, Albright F. The metabolic effects of steroid hormones in osteoporosis. J Clin Invest. 1947 Jan;26(1):24-56.
3. Manolagas SC. From estrogen-centric to aging and oxida-tive stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010 Jun;31(3):266-300.
4. Williams GR. Hypogonadal bone loss: sex steroids or go-nadotropins? Endocrinology. 2007 Jun;148(6):2610-2.
5. Martin TJ, Gaddy D. Bone loss goes beyond estrogen. Nat Med. 2006 Jun;12(6):612-3.
6. Clark PA, Rogol AD. Growth hormones and sex steroid interactions at puberty. Endocrinol Metab Clin North Am. 1996 Sep;25(3):665-81.
7. Cutler GB Jr. The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):141-4.
8. MacGillivray MH, Morishima A, Conte F, Grumbach M, Smith EP. Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiph-yseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor. Horm Res. 1998;49 Suppl 1:2-8.
9. Pitkin RM, Reynolds WA, Williams GA, Hargis GK. Calcium-regulating hormones during the menstrual cycle. J Clin Endocrinol Metab. 1978 Sep;47(3):626-32.
10. Eaves L, Silberg J, Foley D, Bulik C, Maes H, Erkanli A, et al. Genetic and environmental influences on the relative timing of pubertal change. Twin Res. 2004 Oct;7(5):471-81.
11. Brooks-Gunn J. Antecedents and consequences of variations in girls' maturational timing. J Adolesc Health Care. 1988 Sep;9(5):365-73.
12. McKay HA, Bailey DA, Mirwald RL, Davison KS, Faulkner RA. Peak bone mineral accrual and age at men-arche in adolescent girls: a 6-year longitudinal study. J Pe-diatr. 1998 Nov;133(5):682-7.
13. Van Coeverden SC, De Ridder CM, Roos JC, Van't Hof MA, Netelenbos JC, Delemarre-Van de Waal HA. Pubertal maturation characteristics and the rate of bone mass development longitudinally toward menarche. J Bone Miner Res. 2001 Apr;16(4):774-81.
14. Sabatier JP, Guaydier-Souquieres G, Laroche D, Benmalek A, Fournier L, Guillon-Metz F, Delavenne J, Denis AY. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. Osteoporos Int. 1996;6(2):141-48.
15. Kalyan S, Barr SI, Alamoudi R, Prior JC. Is development of ovulatory cycles in adolescence important for peak bone mass? J Bone Min.Res 2007;22(S494):W511.
16. Csermely T, Halvax L, Schmidt E, Zambo K, Vadon G, Szabo I, et al. Occurrence of osteopenia among adolescent girls with oligo/amenorrhea. Gynecol Endocrinol. 2002 Apr;16(2):99-105.
17. Genazzani AD. Neuroendocrine aspects of amenor-rhea related to stress. Pediatr.Endocrinol.Rev. 2005 Jun;2(4):661-8.
18. Guest NS, Barr SI. Cognitive dietary restraint is associated with stress fractures in women runners. Int J Sport Nutr Exerc Metab. 2005 Apr;15(2):147-59.
19. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the patho-physiology of osteoporosis. N Engl J Med. 1995 Feb 2;332(5):305-11.
20. Bilezikjian LM, Vaughan JM, Vale WW. Characterization and the regulation of inhibin/activin subunit proteins of cultured rat anterior pituitary cells. Endocrinology. 1993 Dec;133(6):2545-53.
21. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 1999 Dec;13(15):2105-24.
22. Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction. 2006 Aug;132(2):191-206.
23. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocri-nol Metab. 1996 Apr;81(4):1401-5.
24. Robertson DM, Hale GE, Jolley D, Fraser IS, Hughes CL, Burger HG. Interrelationships between ovarian and pituitary hormones in ovulatory menstrual cycles across reproductive age. J Clin Endocrinol Metab. 2009 Jan;94(1):138-44.
25. Muttukrishna S, Child T, Lockwood GM, Groome NP, Barlow DH, Ledger WL. Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women. Hum Reprod. 2000 Mar;15(3):549-56.
26. Klein NA, Houmard BS, Hansen KR, Woodruff TK, Sluss PM, Bremner WJ, Soules MR. Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women. J Clin Endocrinol Metab. 2004 Jun;89(6):2977-81.
27. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem. 1994 Jul;55(3):273-86.
28. Parfitt AM. Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int. 1979 Aug 24;28(1):1-5.
29. Shevde N, Anklesaria P, Greenberger JS, Bleiberg I, Glowacki J. Stromal cell-mediated stimulation of osteoclastogenesis. Proc Soc Exp Biol Med. 1994 Apr;205(4):306-15.
30. Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD. Changes in bone resorption during the menstrual cycle. J Bone Miner Res. 1999 Apr;14(4):609-15.
31. Gass ML, Kagan R, Kohles JD, Martens MG. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause. 2008 Jul-Aug;15(4 Pt 1):667-75.
32. Gorai I, Chaki O, Nakayama M, Minaguchi H. Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int. 1995 Aug;57(2):100-4.
33. Wreje U, Brynhildsen J, Aberg H, Bystrom B, Hammar M, von Schoultz B. Collagen metabolism markers as a reflection of bone and soft tissue turnover during the menstrual cycle and oral contraceptive use. Contraception. 2000 Apr;61(4):265-70.
34. Prior JC, Hitchcock CL. The endocrinology of perimeno-pause: need for a paradigm shift. Front Biosci. 2011 Jan 1;S3:474-86.
35. Hale GE, Hitchcock CL, Williams LA, Vigna YM, Prior JC. Cyclicity of breast tenderness and night-time vasomo-tor symptoms in mid-life women: information collected using the Daily Perimenopause Diary. Climacteric. 2003 Jun;6(2):128-39.
36. Prior JC. The ageing female reproductive axis II: ovula-tory changes with perimenopause. Novartis Found Symp. 2002;242:172-86; discussion 186-92.
37. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endo-crinol Metab. 2007 Aug;92(8):3060-7.
38. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev. 1998 Aug;19(4):397-428.
39. Cooper GS, Sandler DP. Long-term effects of reproductive-age menstrual cycle patterns on peri- and postmenopausal fracture risk. Am J Epidemiol. 1997 May 1;145(9):804-9.
40. Nicodemus KK, Folsom AR, Anderson KE. Menstrual history and risk of hip fractures in postmenopausal women. The Iowa Women's Health Study. Am J Epidemiol. 2001 Feb 1;153(3):251-5.
41. Hesdorffer DC, Melton LJ. 3rd, Malkasian GD, Atkinson EJ, Brinton LA, O'Fallon WM. Hip fractures among infertile women. Am J Epidemiol. 1999 May 1;149(9):810-3.
42. Ouyang F, Wang X, Arguelles L, Rosul LL, Venners SA, Chen C, et al. Menstrual cycle lengths and bone mineral density: a cross-sectional, population-based study in rural Chinese women ages 30-49 years. Osteoporos Int. 2007 Feb;18(2):221-33.
43. Fox KM, Magaziner J, Sherwin R, Scott JC, Plato CC, Nevitt M, Cummings S. Reproductive correlates of bone mass in elderly women. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1993 Aug;8(8):901-8.
44. Banks E, Reeves GK, Beral V, Balkwill A, Liu B, Roddam A. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLoS Med. 2009 Nov;6(11):e1000181.
45. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010 Feb;24(2):323-34.
46. Barr SI, Prior JC, Vigna YM. Restrained eating and ovu-latory disturbances: possible implications for bone health. Am J Clin Nutr. 1994 Jan;59(1):92-7.
47. Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med. 1990 11/01;323(18):1221-7.
48. Prior JC, Vigna YM, Barr SI, Kennedy S, Schulzer M, Li DK. Ovulatory premenopausal women lose cancellous spinal bone: a five year prospective study. Bone. 1996 Mar;18(3):261-7.
49. Waugh EJ, Polivy J, Ridout R, Hawker GA. A prospective investigation of the relations among cognitive dietary restraint, subclinical ovulatory disturbances, physical activity, and bone mass in healthy young women. Am J Clin Nutr. 2007 Dec;86(6):1791-801.
50. Bedford JL, Prior JC, Barr SI. A prospective exploration of cognitive dietary restraint, subclinical ovulatory disturbances, cortisol, and change in bone density over two years in healthy young women. J Clin Endocrinol Metab. 2010 Jul;95(7):3291-9.
51. Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med. 1994 Jun;96(6):521-30.
52. Prior JC. Progesterone as a bone-trophic hormone. Endocr. Rev. 1990 May;11(2):386-398.
53. Sowers M, Crutchfield M, Bandekar R, Randolph JF, Shapiro B, Schork MA, Jannausch M. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res. 1998 Jul;13(7):1134-40.
54. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Denner-stein L, Hopper JL, Wark JD. Bone turnover markers and bone density across the menopausal transition. J Clin En-docrinol Metab. 1996 Sep;81(9):3366-71.
55. Chapurlat RD, Garnero P, Sornay-Rendu E, Arlot ME, Claustrat B, Delmas PD. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int. 2000;11(6):493-8.
56. Vural F, Vural B, Yucesoy I, Badur S. Ovarian aging and bone metabolism in menstruating women aged 35-50 years. Maturitas. 2005 Oct 16;52(2):147-53.
57. O'Connor KA, Ferrell R, Brindle E, Trumble B, Shofer J, Holman DJ, Weinstein M. Progesterone and ovulation across stages of the transition to menopause. Menopause. 2009 11;16(6):1178-87.
58. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Ya-suda H, Yano K, Morinaga T, Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998 Dec 18;253(2):395-400.
59. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795-823.
60. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000 Sep;141(9):3478-84.
61. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteo-protegerin ligand. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3540-5.
62. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kino-saki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602.
63. Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I. Expression of osteo-protegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL. in human breast tumours. J Clin Pathol. 2006 Jan;59(1):56-63.
64. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad.Sci U S A. 2010 Feb 16;107(7):2989-994.
65. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Bio-phys Res Commun. 2000 Sep 7;275(3):768-75.
66. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997 Nov 13;390(6656):175-9.
67. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006 Jan;12(1):17-25.
68. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003 May 15;423(6937):337-42.
69. Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot.Gene Expr. 2009;19(1):61-72.
70. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999 Apr 15;13(8):1015-024.
71. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem. 1998 Dec 18;273(51):34120-7.
72. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 2000 Oct 6;275(40):31155-61.
73. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, Kim HH. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone. 2002 Jan;30(1):71-7.
74. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF. stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001 Jan 5;276(1):563-8.
75. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yo-shida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of os-teoclasts. Dev Cell. 2002 Dec;3(6):889-901.
76. Baud V, Liu ZG, Bennett B, Suzuki N, Xia Y, Karin M. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 1999 May 15;13(10):1297-308.
77. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med. 1999 Dec 20;190(12):1741-54.
78. Yan T, Riggs BL, Boyle WJ, Khosla S. Regulation of os-teoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem. 2001 Aug 1-9;83(2):320-5.
79. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleu-kin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem. 1996 Nov 15;271(46):28890-7.
80. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest. 1999 Aug;104(4):503-13.
81. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001 Mar 23;276(12):8836-40.
82. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spels-berg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteo-blastic cells. Endocrinology. 1999 Sep;140(9):4367-70.
83. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 2008 Feb 6;27(3):535-45.
84. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007 Sep 7;130(5):811-23.
85. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002 Oct 25;298(5594):843-6.
86. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001 Mar 9;104(5):719-30.
87. Imai Y, Kondoh S, Kouzmenko A, Kato S. Minireview: osteoprotective action of estrogens is mediated by osteo-clastic estrogen receptor-alpha. Mol Endocrinol. 2010 May;24(5):877-85.
88. Freifeld ML, Feil PD, Bardin CW. The in vivo regulation of the progesterone receptor in guinea pig uterus: dependence on estrogen and progesterone. Steroids. 1974 Jan;23(1):93-103.
89. Janne O, Kontula K, Luukkainen T, Vihko R. Oestrogen-induced progesterone receptor in human uterus. J Steroid Biochem. 1975 Mar-Apr;6(3-4):501-9.
90. Boney-Montoya J, Ziegler YS, Curtis CD, Montoya JA, Nardulli AM. Long-range transcriptional control of progesterone receptor gene expression. Mol Endocrinol. 2010 Feb;24(2):346-58.
91. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Grone-meyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990 May;9(5):1603-14.
92. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bi-lancio A, Lombardi M, Gong W, Beato M, Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998 Apr 1;17(7):2008-2018.
93. Slootweg MC, Ederveen AG, Schot LP, Schoonen WG, Kloosterboer HJ. Oestrogen and progestogen synergisti-cally stimulate human and rat osteoblast proliferation. J Endocrinol. 1992 May;133(2):R5-8.
94. Schmidmayr M, Magdolen U, Tubel J, Kiechle M, Burgkart R, Seifert-Klauss V. Progesterone Enhances Differentiation of Primary Human Osteoblasts in Long-Term Cultures. Geburtshilfe Frauenheilkunde 2008;68(7):722-8.
95. Bamberger AM, Bamberger CM, Gellersen B, Schulte HM. Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6169-74.
96. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998 Apr 24;273(17):10696-701.
97. Tseng L, Tang M, Wang Z, Mazella J. Progesterone receptor (hPR) upregulates the fibronectin promoter activity in human decidual fibroblasts. DNA Cell Biol. 2003 Oct;22(10):633-40.
98. Grosse B, Kachkache M, Le Mellay V, Lieberherr M. Membrane signalling and progesterone in female and male osteoblasts. I. Involvement Of intracellular Ca(2+), inosi-tol trisphosphate, and diacylglycerol, but not cAMP. J Cell Biochem. 2000 Aug 2;79(2):334-45.
99. Le Mellay V, Lieberherr M. Membrane signaling and progesterone in female and male osteoblasts. II. Direct involvement of G alpha q/11 coupled to PLC-beta 1 and PLC-beta 3. J Cell Biochem. 2000 Aug 2;79(2):173-81.
100. Revelli A, Massobrio M, Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev. 1998 Feb;19(1):3-17.
101. Moore NL, Narayanan R, Weigel NL. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids. 2007 Feb;72(2):202-9.
102. Zhu Y, Hanna RN, Schaaf MJ, Spaink HP, Thomas P. Candidates for membrane progestin receptors--past approaches and future challenges. Comp Biochem Physiol C. 2008 Nov;148(4):381-9.
103. Thomas P. Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions. Front Neuroendocrinol. 2008 May;29(2):292-312.
104. Labombarda F, Meffre D, Delespierre B, Krivokapic-Blondiaux S, Chastre A, Thomas P, Pang Y, Lydon JP, Gonzalez SL, De Nicola AF, Schumacher M, Guen-noun R. Membrane progesterone receptors localization in the mouse spinal cord. Neuroscience. 2010 Mar 10;166(1):94-106.
105. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003 Jan 24;278(4):2701-12.
106. Ortega N, Behonick DJ, Werb Z. Matrix remodeling during endochondral ossification. Trends Cell Biol. 2004 Feb;14(2):86-93.
107. Luo XH, Liao E Y. Progesterone differentially regulates the membrane-type matrix metalloproteinase-1 (MT1 -MMP) compartment of proMMP-2 activation in MG-63 cells. Horm Metab Res. 2001 Jul;33(7):383-8.
108. Rickard DJ, Iwaniec UT, Evans G, Hefferan TE, Hunter JC, Waters KM, Lydon JP, O'Malley BW, Khosla S, Spels-berg TC, Turner RT. Bone growth and turnover in progesterone receptor knockout mice. Endocrinology. 2008 May;149(5):2383-90.
109. Yao W, Dai W, Shahnazari M, Pham A, Chen Z, Chen H, Guan M, Lane NE. Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice. PLoS One. 2010 Jul 1;5(7):e11410.
110. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006 Jul 19;98(14):1011-4.
111. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lin-deman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature 2010 Jun 10;465(7299):798-802.
112. Gupta R, Alhajri FA, Mohammed AM, Chavan VN, Gupta P. Relationship between mammography breast density and bone mineral density. J Clin Densitom. 2008 Jul-Sep;11(3):431-6.
113. Quinkler M, Kaur K, Hewison M, Stewart PM, Cooper MS. Progesterone is extensively metabolized in osteo-blasts: implications for progesterone action on bone. Horm Metab Res. 2008 Oct;40(10):679-84.
114. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachris-tou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zal-lone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardo-so-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass. Cell. 2006 Apr 21;125(2):247-60.
115. Baron R. FSH versus estrogen: who's guilty of breaking bones? Cell Metab. 2006 May;3(5):302-5.
116. Seibel MJ, Dunstan CR, Zhou H, Allan CM, Handelsman DJ. Sex steroids, not FSH, influence bone mass. Cell. 2006 12/15;127(6):1079.
117. Prior JC. FSH and bone-important physiology or not? Trends Mol Med. 2007 Jan;13(1):1-3.
118. Gao J, Tiwari-Pandey R, Samadfam R, Yang Y, Miao D, Karaplis AC, Sairam MR, Goltzman D. Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology. 2007 Jun;148(6):2613-21.
119. Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S. Effects of Suppression of Follicle Stimulating Hormone Secretion on Bone Resorption Markers in Postmenopausal Women. J Clin Endocrinol Metab. 2010 Nov;95(11):5063-8.
120. van Loenen AC, Huirne JA, Schats R, Hompes PG, Lam-balk CB. GnRH agonists, antagonists, and assisted conception. Semin Reprod Med. 2002 Nov;20(4):349-64.
121. Rendina D, Gianfrancesco F, De Filippo G, Merlotti D, Esposito T, Mingione A, Nuti R, Strazzullo P, Mossetti G, Gennari L. FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol. 2010 Jul;163(1):165-72.
122. Hurwitz JM, Santoro N. Inhibins, activins, and follistatin in the aging female and male. Semin Reprod Med. 2004 Aug;22(3):209-17.
123. Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D. Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin. Mol Cell Endocrinol. 2009 Oct 30;310(1-2):11-20.
124. Bernard DJ, Chapman SC, Woodruff TK. Mechanisms of inhibin signal transduction. Recent Prog Horm Res. 2001;56:417-50.
125. Sakai R, Eto Y, Ohtsuka M, Hirafuji M, Shinoda H. Activin enhances osteoclast-like cell formation in vitro. Biochem. Biophys.Res.Commun. 1993 Aug 31;195(1):39-46.
126. Sakai R, Eto Y. Involvement of activin in the regulation of bone metabolism. Mol.Cell.Endocrinol. 2001 Jun 30;180(1-2):183-188.
127. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal. 2009 Jun 18;7:15.
128. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010 8/20;142(4):531-43.
129. Koseki T, Gao Y, Okahashi N, Murase Y, Tsujisawa T, Sato T, Yamato K, Nishihara T. Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal. 2002 Jan;14(1):31-6.
130. Zhang M, Yan Y, Lim YB, Tang D, Xie R, Chen A, Tai P, Harris SE, Xing L, Qin YX, Chen D.BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts. J Cell Biochem. 2009 Nov 1;108(4):896-905.
131. Teplyuk NM, Zhang Y, Lou Y, Hawse JR, Hassan MQ, Teplyuk VI, Pratap J, Galindo M, Stein JL, Stein GS, Lian JB, van Wijnen AJ. The osteogenic transcription factor runx2 controls genes involved in sterol/steroid metabolism, including CYP11A1 in osteoblasts. Mol Endocrinol. 2009 Jun;23(6):849-61.